# | Title | Journal | Year | Citations |
---|
1 | National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 1—Full Report | Journal of Clinical Lipidology | 2015 | 632 |
2 | Familial Hypercholesterolemia: Screening, diagnosis and management of pediatric and adult patients | Journal of Clinical Lipidology | 2011 | 483 |
3 | National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2 | Journal of Clinical Lipidology | 2015 | 430 |
4 | Familial Hypercholesterolemia: Screening, diagnosis and management of pediatric and adult patients | Journal of Clinical Lipidology | 2011 | 406 |
5 | National Lipid Association recommendations for patient-centered management of dyslipidemia: Part 1 – executive summary | Journal of Clinical Lipidology | 2014 | 396 |
6 | Understanding Statin Use in America and Gaps in Patient Education (USAGE): An internet-based survey of 10,138 current and former statin users | Journal of Clinical Lipidology | 2012 | 395 |
7 | An assessment by the Statin Muscle Safety Task Force: 2014 update | Journal of Clinical Lipidology | 2014 | 391 |
8 | Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial | Journal of Clinical Lipidology | 2015 | 390 |
9 | LDL particle number and risk of future cardiovascular disease in the Framingham Offspring Study—Implications for LDL management | Journal of Clinical Lipidology | 2007 | 365 |
10 | Obesity, adiposity, and dyslipidemia: A consensus statement from the National Lipid Association | Journal of Clinical Lipidology | 2013 | 346 |
11 | Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association | Journal of Clinical Lipidology | 2019 | 315 |
12 | Clinical implications of discordance between low-density lipoprotein cholesterol and particle number | Journal of Clinical Lipidology | 2011 | 311 |
13 | Familial Hypercholesterolemias: Prevalence, genetics, diagnosis and screening recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia | Journal of Clinical Lipidology | 2011 | 292 |
14 | An International Atherosclerosis Society Position Paper: Global recommendations for the management of dyslipidemia-Full report | Journal of Clinical Lipidology | 2014 | 289 |
15 | Hypolipidemia is associated with the severity of COVID-19 | Journal of Clinical Lipidology | 2020 | 278 |
16 | High-density lipoproteins: A consensus statement from the National Lipid Association | Journal of Clinical Lipidology | 2013 | 276 |
17 | “Atherogenic index of plasma” (log10 triglyceride/high-density lipoprotein−cholesterol) predicts high blood pressure, diabetes, and vascular events | Journal of Clinical Lipidology | 2010 | 243 |
18 | Clinical utility of inflammatory markers and advanced lipoprotein testing: Advice from an expert panel of lipid specialists | Journal of Clinical Lipidology | 2011 | 235 |
19 | Effects of eicosapentaenoic acid and docosahexaenoic acid on low-density lipoprotein cholesterol and other lipids: A review | Journal of Clinical Lipidology | 2012 | 229 |
20 | Review of current evidence and clinical recommendations on the effects of low-carbohydrate and very-low-carbohydrate (including ketogenic) diets for the management of body weight and other cardiometabolic risk factors: A scientific statement from the National Lipid Association Nutrition and Lifestyle Task Force | Journal of Clinical Lipidology | 2019 | 225 |
21 | A review of low-density lipoprotein cholesterol, treatment strategies, and its impact on cardiovascular disease morbidity and mortality | Journal of Clinical Lipidology | 2016 | 219 |
22 | Predictors of statin adherence, switching, and discontinuation in the USAGE survey: Understanding the use of statins in America and gaps in patient education | Journal of Clinical Lipidology | 2013 | 210 |
23 | Prevalence of lipid abnormalities in the United States: The National Health and Nutrition Examination Survey 2003–2006 | Journal of Clinical Lipidology | 2012 | 206 |
24 | Fatty acids in cardiovascular health and disease: A comprehensive update | Journal of Clinical Lipidology | 2012 | 201 |
25 | Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: The EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial | Journal of Clinical Lipidology | 2014 | 198 |
26 | An assessment by the Statin Liver Safety Task Force: 2014 update | Journal of Clinical Lipidology | 2014 | 189 |
27 | Cholesterol crystals piercing the arterial plaque and intima trigger local and systemic inflammation | Journal of Clinical Lipidology | 2010 | 158 |
28 | A novel omega-3 free fatty acid formulation has dramatically improved bioavailability during a low-fat diet compared with omega-3-acid ethyl esters: The ECLIPSE (Epanova® compared to Lovaza® in a pharmacokinetic single-dose evaluation) study | Journal of Clinical Lipidology | 2012 | 156 |
29 | Cascade screening based on genetic testing is cost-effective: Evidence for the implementation of models of care for familial hypercholesterolemia | Journal of Clinical Lipidology | 2014 | 149 |
30 | An International Atherosclerosis Society Position Paper: Global recommendations for the management of dyslipidemia | Journal of Clinical Lipidology | 2013 | 147 |
31 | The importance of non–HDL cholesterol reporting in lipid management | Journal of Clinical Lipidology | 2008 | 145 |
32 | Pediatric aspects of Familial Hypercholesterolemias: Recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia | Journal of Clinical Lipidology | 2011 | 142 |
33 | The risks of statin use in pregnancy: A systematic review | Journal of Clinical Lipidology | 2016 | 140 |
34 | Severe hypertriglyceridemia is primarily polygenic | Journal of Clinical Lipidology | 2019 | 136 |
35 | An assessment by the Statin Intolerance Panel: 2014 update | Journal of Clinical Lipidology | 2014 | 135 |
36 | Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: Design and rationale of ODYSSEY ALTERNATIVE, a randomized phase 3 trial | Journal of Clinical Lipidology | 2014 | 128 |
37 | Use of ETC-1002 to treat hypercholesterolemia in patients with statin intolerance | Journal of Clinical Lipidology | 2015 | 128 |
38 | Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor α modulator, in patients with dyslipidemia: Results from a 24-week, randomized, double blind, active-controlled, phase 3 trial | Journal of Clinical Lipidology | 2018 | 127 |
39 | Altered cholesterol and fatty acid metabolism in Huntington disease | Journal of Clinical Lipidology | 2010 | 126 |
40 | A clinician's guide to statin drug-drug interactions | Journal of Clinical Lipidology | 2014 | 124 |
41 | Management of Familial Hypercholesterolemias in adult patients: Recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia | Journal of Clinical Lipidology | 2011 | 120 |
42 | Treatment with ETC-1002 alone and in combination with ezetimibe lowers LDL cholesterol in hypercholesterolemic patients with or without statin intolerance | Journal of Clinical Lipidology | 2016 | 119 |
43 | Unraveling HDL-Associated Risk: Current Challenges and Future Directions | Journal of Clinical Lipidology | 2011 | 115 |
44 | NLA Task Force on Statin Safety - 2014 update | Journal of Clinical Lipidology | 2014 | 114 |
45 | High-density lipoprotein subclasses and their relationship to cardiovascular disease | Journal of Clinical Lipidology | 2012 | 112 |
46 | The effects of adherence and persistence on clinical outcomes in patients treated with statins: A systematic review | Journal of Clinical Lipidology | 2010 | 109 |
47 | Treatment of adults with Familial Hypercholesterolemia and evidence for treatment: Recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia | Journal of Clinical Lipidology | 2011 | 107 |
48 | The risk of cardiovascular events with increased apolipoprotein CIII: A systematic review and meta-analysis | Journal of Clinical Lipidology | 2015 | 106 |
49 | Toward an international consensus—Integrating lipoprotein apheresis and new lipid-lowering drugs | Journal of Clinical Lipidology | 2017 | 105 |
50 | The National Lipid Association scientific statement on coronary artery calcium scoring to guide preventive strategies for ASCVD risk reduction | Journal of Clinical Lipidology | 2021 | 105 |